Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00750841
First received: September 10, 2008
Last updated: September 22, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)